

Gemcitabine Hydrochloride: sc-204763



The Power to Question

MATERIAL SAFETY DATA SHEET

1. PRODUCT AND COMPANY IDENTIFICATION

Product Name: Gemcitabine Hydrochloride
Product Number: sc-204763
Supplier: Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, CA 95060
800.457.3801 or 831.457.3800
Emergency: ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112

2. HAZARDS IDENTIFICATION

Emergency Overview

OSHA Hazards

Reproductive hazard

Target Organs

Female reproductive system.

GHS Classification

Reproductive toxicity (Category 1B)

GHS Label elements, including precautionary statements

Pictogram



Signal word Danger

Hazard statement(s)

H360 May damage fertility or the unborn child.

Precautionary statement(s)

P201 Obtain special instructions before use.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

HMIS Classification

Health hazard: 0

Chronic Health Hazard: *

Flammability: 0

Physical hazards: 0

NFPA Rating

Health hazard: 0

Fire: 0

Reactivity Hazard: 0

Potential Health Effects

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.

Skin May be harmful if absorbed through skin. May cause skin irritation.

Eyes May cause eye irritation.

Ingestion May be harmful if swallowed.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Formula : C₉H₁₁F₂N₃O₄ • HCl

Weight : 299.66 g/mol

<u>CAS-No.</u>	<u>EC-No.</u>	<u>Index-No.</u>	<u>Concentration</u>
Gemcitabine hydrochloride 122111-03-9	—	—	—

4. FIRST AID MEASURES

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire-fighters

Wear self contained breathing apparatus for fire fighting if necessary.

Hazardous combustion products

Hazardous decomposition products formed under fire conditions. – Carbon oxides, nitrogen oxides (NO_x), Hydrogen chloride gas, Hydrogen fluoride

6. ACCIDENTAL RELEASE MEASURES

Personal precautions

Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

7. HANDLING AND STORAGE

Precautions for safe handling

Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Conditions for safe storage

Keep container tightly closed in a dry and well-ventilated place. Light sensitive. Store at 4° C.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment

Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Eye protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin and body protection

impervious clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Hygiene measures

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

9. PHYSICAL AND CHEMICAL PROPERTIES

Form	solid	pH	no data available
Melting point/freezing point	no data available	Boiling point	no data available
Flash point	no data available	Ignition temperature	no data available
Autoignition temperature	no data available	Lower explosion limit	no data available
Upper explosion limit	no data available	Vapour pressure	no data available
Density	no data available	Water solubility	no data available
Relative vapour density	no data available	Odour	no data available
Odour Threshold	no data available	Evaporation rate	no data available
Partition coefficient: n-octanol/water	no data available		

10. STABILITY AND REACTIVITY

Chemical stability

Stable under recommended storage conditions.

Possibility of hazardous reactions

no data available

Conditions to avoid

no data available

Materials to avoid

Strong oxidizing agents

Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. – Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas, Hydrogen fluoride Other decomposition products – no data available

11. TOXICOLOGICAL INFORMATION

Acute toxicity

Oral LD50

no data available

Inhalation LC50

no data available

Dermal LD50

no data available

Other information on acute toxicity

TDLo Parenteral – Human – female – 300 mg/kg

Remarks: Lungs, Thorax, or Respiration:Dyspnea. Lungs, Thorax, or Respiration:Fibrosis, focal (pneumoconiosis).

Lungs, Thorax, or Respiration:Other changes.

LD50 Intravenous – rat – 236 mg/kg

LD50 Intravenous – mouse – 500 mg/kg

Skin corrosion/irritation

no data available

Serious eye damage/eye irritation

no data available

Respiratory or skin sensitization

no data available

Germ cell mutagenicity

no data available

Carcinogenicity

no data available

- IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
- ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
- NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
- OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

Presumed human reproductive toxicant

Teratogenicity

no data available

Suspected human reproductive toxicant

Specific target organ toxicity – single exposure (Globally Harmonized System)

no data available

Specific target organ toxicity – repeated exposure (Globally Harmonized System)

no data available

Aspiration hazard

no data available

Potential health effects

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion May be harmful if swallowed.

Skin May be harmful if absorbed through skin. May cause skin irritation.

Eyes May cause eye irritation.

Signs and Symptoms of Exposure

Fever, Nausea, Vomiting, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Synergistic effects

no data available

Additional Information

Repeated dose toxicity – Mammal

Blood:Thrombocytopenia.

Repeated dose toxicity – Mammal

Blood:Thrombocytopenia.

Repeated dose toxicity – Mammal

Blood:Thrombocytopenia.

Repeated dose toxicity – Mammal

Blood:Thrombocytopenia.

Repeated dose toxicity – Mammal

Repeated dose toxicity – Mammal

Repeated dose toxicity – mouse

Repeated dose toxicity – mouse

12. ECOLOGICAL INFORMATION**Toxicity**

no data available

Bioaccumulative potential

no data available

PBT and vPvB assessment

no data available

Persistence and degradability

no data available

Mobility in soil

no data available

Other adverse effects

no data available

13. DISPOSAL CONSIDERATIONS

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION

OSHA Hazards

Reproductive hazard

SARA 302 Components

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Chronic Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Gemcitabine hydrochloride

CAS-No.: 122111-03-9

New Jersey Right To Know Components

Gemcitabine hydrochloride

CAS-No.: 122111-03-9

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be complete and should be used only as a guide. The burden of safe use of this material rests entirely with the user.

4/5/2011